These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21422355)

  • 1. Successful laser treatment of vandetanib-associated cutaneous pigmentation.
    Brooks S; Linehan WM; Srinivasan R; Kong HH
    Arch Dermatol; 2011 Mar; 147(3):364-5. PubMed ID: 21422355
    [No Abstract]   [Full Text] [Related]  

  • 2. Cutaneous pigmentation after photosensitivity induced by vandetanib therapy.
    Kong HH; Fine HA; Stern JB; Turner ML
    Arch Dermatol; 2009 Aug; 145(8):923-5. PubMed ID: 19687425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.
    Giacchero D; Ramacciotti C; Arnault JP; Brassard M; Baudin E; Maksimovic L; Mateus C; Tomasic G; Wechsler J; Schlumberger M; Robert C
    Arch Dermatol; 2012 Dec; 148(12):1418-20. PubMed ID: 23247489
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral mucosal pigmentation induced by vandetanib therapy: First clinicopathological characterization.
    Vigarios E; Maret D; Herbaut-Barres B; Zerdoud S; Sibaud V
    Oral Oncol; 2020 Oct; 109():104747. PubMed ID: 32418862
    [No Abstract]   [Full Text] [Related]  

  • 5. Vandetanib and the management of advanced medullary thyroid cancer.
    Campbell MJ; Seib CD; Gosnell J
    Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
    Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
    Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vandetanib for the treatment of medullary thyroid cancer.
    Chau NG; Haddad RI
    Clin Cancer Res; 2013 Feb; 19(3):524-9. PubMed ID: 23231950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective use of vandetanib in the treatment of thyroid cancer.
    Fallahi P; Di Bari F; Ferrari SM; Spisni R; Materazzi G; Miccoli P; Benvenga S; Antonelli A
    Drug Des Devel Ther; 2015; 9():3459-70. PubMed ID: 26170630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 10. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Robinson BG; Paz-Ares L; Krebs A; Vasselli J; Haddad R
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2664-71. PubMed ID: 20371662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of vandetanib for the treatment of thyroid cancer.
    Tsang VH; Robinson BG; Learoyd DL
    Expert Opin Drug Saf; 2016 Aug; 15(8):1107-13. PubMed ID: 27301016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib.
    Pilco Teran M; Merino Ribas A; Martin Alemany N; Barros Freiria X; Rubio Casadevall J; Pérez Bueno F; García Méndez I; Castillo Devia M; Noboa Paez C; Torguet Escuder P; Calabia Martínez J
    Invest New Drugs; 2021 Feb; 39(1):237-239. PubMed ID: 32648118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
    Natale RB; Thongprasert S; Greco FA; Thomas M; Tsai CM; Sunpaweravong P; Ferry D; Mulatero C; Whorf R; Thompson J; Barlesi F; Langmuir P; Gogov S; Rowbottom JA; Goss GD
    J Clin Oncol; 2011 Mar; 29(8):1059-66. PubMed ID: 21282542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
    Rosen AC; Wu S; Damse A; Sherman E; Lacouture ME
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1125-33. PubMed ID: 22378813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
    Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinase inhibitors for advanced medullary thyroid carcinoma.
    Schlumberger M; Massicotte MH; Nascimento CL; Chougnet C; Baudin E; Leboulleux S
    Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):125-9. PubMed ID: 22584717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report.
    Yin Y; Qiu XY; Zhang YH; Zhang B
    Medicine (Baltimore); 2019 Aug; 98(31):e16392. PubMed ID: 31374006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe photosensitivity reaction to vandetanib.
    Chang CH; Chang JW; Hui CY; Yang CH
    J Clin Oncol; 2009 Sep; 27(27):e114-5. PubMed ID: 19564539
    [No Abstract]   [Full Text] [Related]  

  • 19. Q-switched laser treatment of amiodarone pigmentation.
    Bernstein EF
    J Drugs Dermatol; 2011 Nov; 10(11):1316-9. PubMed ID: 22052315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gray-bluish cutaneous pigmentation and ice-pick scars induced by vandetanib therapy.
    Cuenca-Barrales C; López-Delgado D; Cáncela-Díez B; Galvez-Moreno M; Ruiz-Villaverde R
    Int J Dermatol; 2018 Jul; 57(7):e33-e34. PubMed ID: 29638004
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.